Savara (NASDAQ:SVRA) Sees Large Volume Increase – Should You Buy?

Shares of Savara Inc. (NASDAQ:SVRA) saw an uptick in trading volume on Monday . 2,459,711 shares changed hands during trading, an increase of 65% from the previous session’s volume of 1,488,669 shares.The stock last traded at $6.8450 and had previously closed at $6.92.

Analysts Set New Price Targets

SVRA has been the subject of several recent analyst reports. HC Wainwright raised their price objective on shares of Savara from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, September 3rd. Guggenheim lifted their target price on shares of Savara from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, September 9th. Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Wednesday, October 8th. Finally, Oppenheimer boosted their target price on shares of Savara from $8.00 to $9.00 and gave the company an “outperform” rating in a report on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.29.

Savara Price Performance

The company has a debt-to-equity ratio of 0.32, a current ratio of 7.65 and a quick ratio of 7.65. The firm’s 50 day moving average is $4.65 and its 200 day moving average is $3.45. The firm has a market cap of $1.33 billion, a P/E ratio of -12.33 and a beta of 0.22.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). As a group, analysts anticipate that Savara Inc. will post -0.45 earnings per share for the current year.

Institutional Investors Weigh In On Savara

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Sivia Capital Partners LLC raised its stake in Savara by 9.1% during the 2nd quarter. Sivia Capital Partners LLC now owns 41,500 shares of the company’s stock valued at $95,000 after purchasing an additional 3,459 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after acquiring an additional 4,626 shares during the last quarter. Farther Finance Advisors LLC grew its stake in Savara by 17.6% during the second quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock valued at $87,000 after acquiring an additional 5,687 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Savara by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after acquiring an additional 6,449 shares during the last quarter. Finally, Sio Capital Management LLC lifted its stake in Savara by 1.0% in the 2nd quarter. Sio Capital Management LLC now owns 726,851 shares of the company’s stock worth $1,657,000 after purchasing an additional 7,197 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.